Glutamate Receptors and Synaptic Plasticity in Health and Disease: A Personal Journey
Hippocampus, Volume 36, Issue 1, January 2026.ABSTRACT I describe my progress in understanding synaptic plasticity in the hippocampus. Over the decades my lab has focused on the roles of glutamate receptors (AMPARs, NMDARs, mGluRs and KARs) and associated signaling molecules in LTP and LTD. Most of our studies have been conducted in area CA1 (Schaffer collateral—commissural pathway) with some ...
Graham L. Collingridge
wiley +1 more source
Vitamins in the Treatment of Periodontitis: Molecular Mechanism and Network Pharmacological Analysis. [PDF]
Oral Health Prev DentWang LR, Liu DX, Yu L, Gao L.
europepmc +1 more source
Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review
Health Science Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background and Aims Alzheimer's disease (AD) is a progressive neurodegenerative disorder of aging characterized by memory loss and cognitive decline, associated with amyloid‐β toxicity, tau hyperphosphorylation, and neurofibrillary tangle formation. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) affects the central nervous system
Teesta Bhowmick +5 more
wiley +1 more source
Transposable Element-Derived miR-28-5p and miR-708-5p: Exploring Potential Roles in Lung Cancer. [PDF]
Noncoding RNAChira S +4 more
europepmc +1 more source
Interdisciplinary Medicine, Volume 4, Issue 1, January 2026.Schematic representation of nanoparticle‐integrated electrostimulation‐responsive biomaterials for controlled drug delivery and tissue regeneration. Electroactive scaffolds including conductive polymers, electroresponsive hydrogels, and piezoelectric matrices are shown incorporating therapeutic nanoparticles (such as iron oxide, silver, and carbon ...
Peyman Halvaeikhanekahdani +3 more
wiley +1 more source
Amyloid-β, Tau, and α-Synuclein Protein Interactomes as Therapeutic Targets in Neurodegenerative Diseases. [PDF]
Cell Mol NeurobiolMohan Kumar D, Talwar P.
europepmc +1 more source
Melanoma: Pathogenesis and Targeted Therapy
MedComm, Volume 7, Issue 1, January 2026.The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu +5 more
wiley +1 more source
Mastering Organoid Growth: A Complete Guide to Overcoming Methodological Challenges
MedComm, Volume 7, Issue 1, January 2026.Organoids offer transformative 3D models that precisely mimic human organ architecture and function. This review details the latest methodology, emphasizing the cultivation of liver and other abdominal organoids. We analyze technological challenges (e.g., nutrient delivery, scalability, diversity) and provide practical insights for new researchers ...
Chunbao Jiao +12 more
wiley +1 more source
Network Pharmacology and Molecular Docking Identify Medicarpin as a Potent CASP3 and ESR1 Binder Driving Apoptotic and Hormone-Dependent Anticancer Activity. [PDF]
Int J Mol SciRattanapan Y +7 more
europepmc +1 more source
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source